Neurodegenerative disease and REM behavior disorder

Current Treatment Options in Neurology

Volumn 14, Issue 5, 2012, Pages 474-492

  Malhotra, Raman ^a   Avidan, Alon Y ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ALS; Alzheimer's disease; Circadian rhythm disorder; Cognitive behavioral therapy for insomnia; Continuous positive airway pressure (CPAP); Dementia; Hypersomnia; Insomnia; Motor neuron disease; Narcolepsy; Neurodegenerative disease; Parkinson's disease; REM sleep behavior disorder (RBD); Sleep apnea; Sundowning

Indexed keywords

ARMODAFINIL; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; CLONAZEPAM; DONEPEZIL; DOXEPIN; ESZOPICLONE; FERROUS SULFATE; FLUVOXAMINE; GABAPENTIN ENACARBIL; HYPNOTIC AGENT; IMIPRAMINE; LEVODOPA; LINEZOLID; MELATONIN; METHYLPHENIDATE; MODAFINIL; PLACEBO; PRAMIPEXOLE; PRIMIDONE; QUETIAPINE; RAMELTEON; ROPINIROLE; ROTIGOTINE; UNINDEXED DRUG; WARFARIN; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ABDOMINAL PAIN; ADVANCED SLEEP PHASE SYNDROME; AEROBIC EXERCISE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BEDTIME DOSAGE; BODY POSITION; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DECREASED APPETITE; DEGENERATIVE DISEASE; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; HALLUCINATION; HUMAN; HYPERSOMNIA; HYPERTENSION; HYPNOSIS; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; NAUSEA; ORTHODONTIC DEVICE; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PERIODIC LIMB MOVEMENT DISORDER; PHOTOTHERAPY; PHYSIOTHERAPY; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SOMNOLENCE; TASTE DISORDER; UVULOPALATOPHARYNGOPLASTY; VOMITING; WEIGHT REDUCTION;

EID: 84870857795     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0194-5     Document Type: Article

References (79)

1. Bhatt MH, Podder N, Chokroverty S. Sleep and neurodegenerative diseases. Semin Neurol. 2005;25 (1):39-51.
2. Verbaan D, et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007;69 (4):333-41.
3. Bliwise DL, et al. Incident sleep disordered breathing in old age. J Gerontol A Biol Sci Med Sci. 2010;65 (9):997-1003.
4. Asai H, et al. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Clin Neurol Neurosurg. 2009;111(4):341-4.
5. Bliwise DL. Sleep in normal aging and dementia. Sleep. 1993;16(1):40-81.
6. Bliwise DL. Sleep disorders in Alzheimer's disease and other dementias. Clin Cornerstone. 2004;6 (Suppl 1A):S16-28.
7. Ferguson KA, et al. Sleep-disordered breathing in amyotrophic lateral sclerosis. Chest. 1996;110(3):664-9.
8. Sixel-Doring F, et al. Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med. 2009;10 (4):407-15.
9. Roche S, et al. Sleep and vigilance in corticobasal degeneration: a descriptive study. Neurophysiol Clin. 2007;37(4):261-4.
10. Motohashi Y, et al. Circadian rhythm abnormalities of wrist activity of institutionalized dependent el-derly persons with dementia. J Gerontol A Biol Sci Med Sci. 2000;55(12):M740-3.
11. McCurry SM, et al. Increasing walking and bright light exposure to improve sleep in communitydwelling persons with Alzheimer's disease: results of a randomized, controlled trial. J Am Geriatr Soc. 2011;59(8):1393-402.
12. McCurry SM, et al. Nighttime insomnia treatment and education for Alzheimer's disease: a randomized, controlled trial. J Am Geriatr Soc. 2005;53(5):793-802.
13. Tandberg E, Larsen JP, Karlsen K. A communitybased study of sleep disorders in patients with Parkinson's disease. Mov Disord. 1998;13(6):895-9.
14. Budur K, Rodriguez C, and Foldvary-Schaefer N. Advances in treating insomnia. Cleve Clin J Med. 2007; 74(4): 251-2, 255-8, 261-2 passim.
15. Menza M, et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708-14.
16. Medeiros CA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254(4):459-64.
17. Juri C, et al. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol. 2005;28(4):185-7.
18. Sloane PD, et al. High-intensity environmental light in dementia: effect on sleep and activity. J Am Geriatr Soc. 2007;55(10):1524-33.
19. Dowling GA, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56(2):239-46.
20. Riemersma-van der Lek RF, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299 (22):2642-55.
21. Giles TL, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006; 3: CD001106.
22. Chong MS, et al. Continuous positive airway pressure reduces subjective daytime sleepiness in patients with mild to moderate Alzheimer's disease with sleep disordered breathing. J Am Geriatr Soc. 2006;54 (5):777-81.
23. Cooke JR, et al. Continuous positive airway pressure deepens sleep in patients with Alzheimer's disease and obstructive sleep apnea. Sleep Med. 2009;10 (10):1101-6.
24. Cooke JR, et al. Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer's disease and obstructive sleep apnea: a preliminary study. J Clin Sleep Med. 2009;5 (4):305-9.
25. Ancoli-Israel S, et al. Cognitive effects of treating obstructive sleep apnea in Alzheimer's disease: a randomized controlled study. J Am Geriatr Soc. 2008;56(11):2076-81.
26. Bourke SC, et al. Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology. 2003;61(2):171-7.
27. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5 (2):173-8.
28. Peppard PE, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. Jama. 2000;284(23):3015-21.
29. Morgenthaler TI, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep. 2006;29(8):1031-5.
30. Permut I, et al. Comparison of positional therapy to CPAP in patients with positional obstructive sleep apnea. J Clin Sleep Med. 2010;6(3):238-43.
31. Moraes W, et al. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest. 2008;133(3):677-83.
32. Sukys-Claudino L, et al. Beneficial effect of donepezil on obstructive sleep apnea: a double-blind, placebocontrolled clinical trial. Sleep Med. 2012;13(3):290-6.
33. Berry RB, Kryger MH, Massie CA. A novel nasal expiratory positive airway pressure (EPAP) device for the treatment of obstructive sleep apnea: a randomized controlled trial. Sleep. 2011;34(4):479-85.
34. Eastwood PR, et al. Treating obstructive sleep apnea with hypoglossal nerve stimulation. Sleep. 2011;34 (11):1479-86.
35. Hogl B, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905-9.
36. Ondo WG, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-9.
37. Adler CH, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003;18 (3):287-93.
38. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord. 2007;22 (14):2070-6.
39. Ondo WG, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65 (10):1337-40.
40. Allen RP, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101-19.
41. Berger K, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004;164(2):196-202.
42. Krishnan PR, Bhatia M, Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord. 2003;18(2):181-5.
43. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421-4.
44. Abele M, et al. Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3. J Neurol. 2001;248 (4):311-4.
45. Schols L, et al. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology. 1998;51(6):1603-7.
46. Banno K, et al. Restless legs syndrome in 218 patients: associated disorders. Sleep Med. 2000;1 (3):221-9.
47. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23(3):200-3.
48. Manconi M, et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med. 2007;8(5):491-7.
49. Allen R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27 (5):907-14.
50. Gabapentin encarbil (Horizant) for restless leg syndrome. Med Lett Drugs Ther. 2011; 53(1372): 70-1.
51. mobileMicromedex®, Micromedex 2.0, 2012.
52. Mitler MM, et al. Nocturnal myoclonus: Treatment efficacy of clonazepam and temazepam. Sleep. 1986;9:385-92.
53. Kaplan P, et al. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levidopa and propoxyphene. Sleep. 1993;16(8):717-23.
54. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19 (3):205-13.
55. Kavey N, et al. Opioid treatment of periodic movements in sleep in patients without restless legs. Neuropeptides. 1988;11(4):181-4.
56. Wetter TC, Pollmacher T. Restless legs and periodic leg movements in sleep syndromes. J Neurol. 1997;244(4 Suppl 1):S37-45.
57. Earley CJ, Allen RP, Hening W. Restless legs syndrome and periodic leg movements in sleep. Handb Clin Neurol. 2011;99:913-48.
58. Ancoli-Israel S, et al. Sleep apnea and periodic movements in an aging sample. J Gerontol. 1985;40 (4):419-25.
59. Carelli G, et al. Periodic limb movements and obstructive sleep apneas before and after continuous positive airway pressure treatment. J Sleep Res. 1999;8(3):211-6.
60. Ancoli-Israel S, Bliwise DL, and Mant A. Sleep and breathing in the elderly. Sleep and Breathing, ed. S.C. Saunders NA1993, New York: Mercel Dekker, Inc. 673-693.
61. Comella CL, et al. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998;51:526-9.
62. Eisehsehr I, et al. Sleep in Lennox-Gastaut syndrome: the role of the cyclic alternating pattern (CAP) in the gate control of clinical seizures and generalized polyspikes. Epilepsy Res. 2001;46:241-50.
63. Aurora RN, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85-95.
64. Schenck CH, Mahowald MW. Polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Cleve Clin J Med. 1990;57(Suppl):S9-S23.
65. Mahowald MW, Schenck CH. REM sleep behavior disorder. In: Kryger MH, Dement W, Roth T, editors. The Principles and Practice of Sleep Medicine. Philadelphia: WB Saunders; 1994. p. 574-88.
66. Mahowald MW, Ettinger MG. Things that go bump in the night: The parasomnias revisited. J Clin Neurophysiol. 1990;7:119-43.
67. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281-4.
68. EBSCO Industries, I., Dyna Med, 2012.
69. Takeuchi N, et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci. 2001;55 (3):267-9.
70. Boeve B. Melatonin for treatment of REM sleep behavior disorder: response in 8 patients. Sleep. 2001;24(suppl):A35.
71. Fantini ML, et al. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003;61:1418-20.
72. Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord. 1996;11:214-6.
73. Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med. 2009;5 (3):235-9.
74. Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639-644A.
75. Reid KJ, Chang AM, Zee PC. Circadian rhythmsleep disorders. Med ClinNorth Am. 2004;88(3):631-51. viii.
76. Reid KJ, Zee PC. Circadian rhythm disorders. Semin Neurol. 2004;24(3):315-25.
77. Lack L, Wright H. The effect of evening bright light in delaying the circadian rhythms and lengthening the sleep of early morning awakening insomniacs. Sleep. 1993;16(5):436-43.
78. Lack L, Schumacher K. Evening light treatment of early morning insomnia. Sleep Res. 1993;22:225.
79. Ancoli-Israel S, et al. Identification and treatment of sleep problems in the elderly. Sleep Med Rev. 1997;1 (1):3-17.